Inferring haplotypes at the NAT2 locus: The computational approach

BMC Genetics

Volumn 6, Issue , 2005, Pages

  Sabbagh, Audrey ^a,b   Darlu, Pierre ^a  

^a INSERM   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; DNA;

ACCURACY; ALGORITHM; ANALYTIC METHOD; ARTICLE; BAYES THEOREM; COMPUTER PROGRAM; CONTROLLED STUDY; DNA STRAND; DRUG RESPONSE; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; MATHEMATICAL COMPUTING; MAXIMUM LIKELIHOOD METHOD; MONTE CARLO METHOD; MUTATIONAL ANALYSIS; PARSIMONY ANALYSIS; POPULATION GENETICS; PROBABILITY; RELIABILITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 25444438753     PISSN: 14712156     EISSN: 14712156     Source Type: Journal    
DOI: 10.1186/1471-2156-6-30     Document Type: Article

References (63)

1. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF, Kadlubar FF: N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun 1992, 185:839-844.
2. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM: Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993, 14:1633-1638.
3. Hein DW: Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002, 506-507:65-77.
4. Meisel P: Arylamine N-acetyltransferases and drug response. Pharmacogenomics 2002, 3:349-366.
5. Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM: Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996, 6:177-185.
6. Asprodini EK, Zifa E, Papageorgiou I, Benakis A: Determination of N-acetylation phenotyping in a Greek population using caffeine as a metabolic probe. Eur J Drug Metab Pharmacokinet 1998, 23:501-506.
7. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA: Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982, 2:842-845.
8. Risch A, Wallace DM, Bathers S, Sim E: Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995, 4:231-236.
9. Bialecka M, Gawronska-Szklarz B, Drozdzik M, Honczarenko K, Stankiewicz J: N-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population. Eur J Clin Pharmacol 2002, 57:857-862.
10. Chan DK, Lam MK, Wong R, Hung WT, Wilcken DE: Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese. Neurology 2003, 60:1002-1005.
11. Blum M, Grant DM, McBride W, Heim M, Meyer UA: Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990, 9:193-203.
12. Ohsako S, Deguchi T: Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 1990, 265:4630-4634.
13. Blum M, Demierre A, Grant DM, Heim M, Meyer UA: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991, 88:5237-5241.
14. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R: Human acetyltransferase polymorphisms. Mutat Res 1997, 376:61-70.
15. Upton A, Johnson N, Sandy J, Sim E: Arylamine N-acetyltransferases - of mice, men and microorganisms. Trends Pharmacol Sci 2001, 22:140-146.
16. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV et al.: Nomenclature for N-acetyltransferases. Pharmacogenetics 1995, 5:1-17.
17. Hein DW, Grant DM, Sim E : Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 2000, 10:291-292.
18. Xu CF, Lewis K, Cantone KL, Khan P, Donnelly C, White N, Crocker N, Boyd PR, Zaykin DV, Purvis IJ: Effectiveness of computational methods in haplotype prediction. Hum Genet 2002, 110:148-156.
19. Judson R, Stephens JC, Windemuth A: The predictive power of haplotypes in clinical response. Pharmacogenomics 2000, 1:15-26.
20. Judson R, Stephens JC: Notes from the SNP vs. haplotype front. Pharmacogenomics 2001, 2:7-10.
21. McDonald OG, Krynetski EY, Evans WE: Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using longrange polymerase chain reaction and intramolecular ligation. Pharmacogenetics 2002, 12:93-99.
22. Zschieschang P, Hiepe F, Gromnica-Ihle E, Roots I, Cascorbi I: Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. Pharmacogenetics 2002, 12:559-563.
23. Agundez JA, Ladero JM, Olivera M, Lozano L, Fernandez-Arquero M, de laConcha EG, Diaz-Rubio M, Benitez J : N-acetyltransferase 2 polymorphism is not related to the risk of advanced alcoholic liver disease. Scand J Gastroenterol 2002, 37:99-103.
24. Loktionov A, Moore W, Spencer SP, Vorster H, Nell T, O'Neill IK, Bingham SA, Cummings JH: Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect Prev 2002, 26:15-22.
25. Cascorbi I, Roots I: Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 1999, 9:123-127.
26. Dandara C, Masimirembwa CM, Magimba A, Kaaya S, Sayi J, Sommers de K, Snyman JR, Hasler JA: Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C>T and 590G>A. Pharmacogenetics 2003, 13:55-58.
27. Anitha A, Banerjee M: Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. Int J Mol Med 2003, 11:125-131.
28. Martinez C, Agundez JA, Olivera M, Martin R, Ladero JM, Benitez J: Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995, 5:207-214.
29. Agundez JA, Olivera M, Martinez C, Ladero JM, Benitez J: Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996, 6:423-428.
30. Martinez C, Agundez JA, Olivera M, Llerena A, Ramirez R, Hernandez M, Benitez J: Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic population. Clin Pharmacol Ther 1998, 63:623-628.
31. Lee SY, Lee KA, Ki CS, Kwon OJ, Kim HJ, Chung MP, Suh GY, Kim JW: Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem 2002, 48:775-777.
32. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I: Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995, 57:581-592.
33. Mrozikiewicz PM, Cascorbi I, Brockmoller J, Roots I. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 1996; 59:376-382.
34. Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Roots I: Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. Pharmacogenetics 1997, 7:327-331.
35. Meisel P, Schroeder C, Wulff K, Siegmund W: Relationship between human genotype and phenotype of N-acetyltransferase (NAT2) as estimated by discriminant analysis and multiple linear regression:1. Genotype and N-acetylation in vivo. Pharmacogenetics 1997, 7:241-246.
36. Kukongviriyapan V, Prawan A, Tassaneyakul W, Aiemsa-Ard J, Warasiha B: Arylamine N-acetyltransferase-2 genotypes in the Thai population. Br J Clin Pharmacol 2003, 55:278-281.
37. Niu T: Algorithms for inferring haplotypes. Genet Epidemiol 2004, 27:334-347.
38. Fallin D, Schork NJ: Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet 2000, 67:947-959.
39. Lin S, Cutler DJ, Zwick ME, Chakravarti A: Haplotype inference in random population samples. Am J Hum Genet 2002, 71:1129-1137.
40. Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y, Saito M, Yamanaka H, Saito T, Kamatani N : Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002, 29:2492-2499.
41. Jorge-Nebert LF, Eichelbaum M, Griese EU, Inaba T, Arias TD : Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. Pharmacogenetics 2002, 12:39-48.
42. Barrett JH, Smith G, Waxman R, Gooderham N, Lightfoot T, Garner RC, Augustsson K, Wolf CR, Bishop DT, Forman D: Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis 2003, 24:275-282.
43. Clark AG: Inference of haplotypes from PCR-amplified samples of diploid populations. Mol Biol Evol 1990, 7:111-122.
44. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989.
45. Agundez JA, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, Benitez J: Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996, 6:501-512.
46. Wang L, Xu Y: Haplotype inference by maximum parsimony. Bioinformatics 2003, 19:1773-1780.
47. Dempster AP, Laird NM, Rubin DB: Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc 1977, 39:1-38.
48. Excoffier L, Slatkin M: Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995, 12:921-927.
49. Hawley ME, Kidd KK: HAPLO: a program using the EM algorithm to estimate the frequencies of multi-site haplotypes. J Hered 1995, 86:409-411.
50. Long JC, Williams RC, Urbanek M: An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995, 56:799-810.
51. Schneider S, Roessli D, Excoffier L: Arlequin ver. 2.000: a software for population genetics data analysis. Genetics and Biometry Laboratory, University of Geneva, Switzerland; 2000.
52. Qin ZS, Niu T, Liu JS: Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 2002, 71:1242-1247.
53. Niu T, Qin ZS, Xu X, Liu JS: Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. Am J Hum Genet 2002, 70:157-169.
54. Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003, 73:1162-1169.
55. Hudson RR: Gene genealogies and the coalescent process. In Oxford surveys in evolutionary biology. Volume 7. Edited by Futuyma D, Antonovics J. Oxford University Press, Oxford; 1991:1-44.
56. Renkonen O: Statisch-ökologische Untersuchungen über die terrestiche Kaferwelt der finnishen Bruchmoore. Ann Zool Soc Bot Fenn Vanamo 1938, 6:1-231.
57. Tishkoff SA, Pakstis AJ, Ruano G, Kidd KK : The accuracy of statistical methods for estimation of haplotype frequencies: an example from the CD4 locus. Am J Hum Genet 2000, 67:518-522.
58. Devlin B, Risch N: A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995, 29:311-322.
59. Liu K, Muse S: PowerMarker: new genetic data analysis software. Version 3.0. Free program distributed by the author over the internet from http://www.powermarker.net
60. Abecasis GR, Cookson WO: GOLD - graphical overview of linkage disequilibrium. Bioinformatics 2000, 16:182-183.
61. Stephens M, Smith NJ, Donnelly P: Reply to Zhang et al. Am J Hum Genet 2001, 69:912-914.
62. Osier M, Pakstis AJ, Kidd JR, Lee JF, Yin SJ, Ko HC, Edenberg HJ, Lu RB, Kidd KK : Linkage disequilibrium at the ADH2 and ADH3 loci and risk of alcoholism. Am J Hum Genet 1999, 64:1147-1157.
63. Zhao H, Pfeiffer R, Gail MH: Haplotype analysis in population genetics and association studies. Pharmacogenomics 2003, 4:171-178.